Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTRAZZA vs BENLYSTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapy,Lupus nephritis (in combination with standard therapy)
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
Intravenous: 100% (not applicable to other routes).
SC: ~82% relative to IV; IV: 100%.
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD. Use caution and consider benefit-risk.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Safety and effectiveness in pediatric patients have not been established.
In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.
No black box warnings.
No FDA black box warning.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
Hypersensitivity reactions including anaphylaxis,Infusion reactions,Increased risk of serious infections, including tuberculosis and opportunistic infections,Malignancy risk (potential),Hypogammaglobulinemia,Depression and suicidality
No known contraindications from the manufacturer.
None known; caution in patients with severe active infections.
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
No known food interactions. May be taken without regard to meals.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as Ig G crosses placenta after 13 weeks gestation. Third trimester: Ig G actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
No dose adjustment recommended based on pregnancy pharmacokinetic changes. However, caution advised due to limited data. Dose may need adjustment if concomitant immunosuppressants used.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
BENLYSTA (belimumab) is a BLy S-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
Report any signs of allergic reaction during or after infusion immediately.,Avoid live vaccines during treatment and for at least 30 days after stopping.,Inform doctor of any new or worsening neurological symptoms.,Use effective contraception during therapy and for 4 months after last dose.,Do not stop or change dose without consulting your rheumatologist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTRAZZA vs BENLYSTA, answered by our medical review team.
PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. BENLYSTA is a Monoclonal Antibody that works by Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTRAZZA and BENLYSTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. The standard adult dose of BENLYSTA is: 10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTRAZZA and BENLYSTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. BENLYSTA is classified as Category C. First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell dep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.